NO952974L - G-CSF-analogpreparater og fremgangsmåter - Google Patents

G-CSF-analogpreparater og fremgangsmåter

Info

Publication number
NO952974L
NO952974L NO952974A NO952974A NO952974L NO 952974 L NO952974 L NO 952974L NO 952974 A NO952974 A NO 952974A NO 952974 A NO952974 A NO 952974A NO 952974 L NO952974 L NO 952974L
Authority
NO
Norway
Prior art keywords
analogs
csf
methods
another aspect
csf analog
Prior art date
Application number
NO952974A
Other languages
English (en)
Other versions
NO952974D0 (no
Inventor
Timothy D Osslund
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21743861&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO952974(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of NO952974D0 publication Critical patent/NO952974D0/no
Publication of NO952974L publication Critical patent/NO952974L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
NO952974A 1993-01-28 1995-07-27 G-CSF-analogpreparater og fremgangsmåter NO952974L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/010,099 US5581476A (en) 1993-01-28 1993-01-28 Computer-based methods and articles of manufacture for preparing G-CSF analogs
PCT/US1994/000913 WO1994017185A1 (en) 1993-01-28 1994-01-25 G-csf analog compositions and methods

Publications (2)

Publication Number Publication Date
NO952974D0 NO952974D0 (no) 1995-07-27
NO952974L true NO952974L (no) 1995-09-28

Family

ID=21743861

Family Applications (3)

Application Number Title Priority Date Filing Date
NO952974A NO952974L (no) 1993-01-28 1995-07-27 G-CSF-analogpreparater og fremgangsmåter
NO20031497A NO20031497D0 (no) 1993-01-28 2003-04-02 Datamaskinbasert apparat for fremvisning av den tredimensjonale struktur til et molekyl og fremgangsmåte for krystallisering av et protein
NO20093489A NO20093489L (no) 1993-01-28 2009-12-08 Datamaskinbasert apparat for fremvisning av den tredimensjonale struktur til et molekyl og fremgangsmate for krytallisering av et protein

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO20031497A NO20031497D0 (no) 1993-01-28 2003-04-02 Datamaskinbasert apparat for fremvisning av den tredimensjonale struktur til et molekyl og fremgangsmåte for krystallisering av et protein
NO20093489A NO20093489L (no) 1993-01-28 2009-12-08 Datamaskinbasert apparat for fremvisning av den tredimensjonale struktur til et molekyl og fremgangsmate for krytallisering av et protein

Country Status (21)

Country Link
US (6) US5581476A (no)
EP (8) EP0974655A3 (no)
JP (7) JPH08506018A (no)
KR (2) KR100390338B1 (no)
CN (3) CN1495197B (no)
AT (2) ATE195552T1 (no)
AU (2) AU697451B2 (no)
CA (4) CA2153896C (no)
DE (1) DE69425516T2 (no)
DK (3) DK0612846T3 (no)
ES (3) ES2422269T3 (no)
FI (2) FI120769B (no)
GR (1) GR3034745T3 (no)
IL (6) IL108446A (no)
LU (1) LU92265I2 (no)
LV (1) LV12642B (no)
NO (3) NO952974L (no)
NZ (5) NZ332188A (no)
PT (3) PT612846E (no)
WO (1) WO1994017185A1 (no)
ZA (1) ZA94568B (no)

Families Citing this family (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020177688A1 (en) * 1988-12-22 2002-11-28 Kirin-Amgen, Inc., Chemically-modified G-CSF
EP0401384B1 (en) * 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US20030053982A1 (en) * 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JP3708151B2 (ja) * 1994-12-15 2005-10-19 協和醗酵工業株式会社 Ｐｅｇ化したヒト顆粒球コロニー刺激因子の定量法
US20030185792A1 (en) * 1996-01-22 2003-10-02 Curis, Inc. Morphogen analogs of bone morphogenic proteins
JP2000501744A (ja) * 1996-01-22 2000-02-15 クリエイティブ バイオモレキゥルズ，インコーポレーテッド モルホゲン類似体およびその製法
US5835382A (en) 1996-04-26 1998-11-10 The Scripps Research Institute Small molecule mimetics of erythropoietin
US6128582A (en) * 1996-04-30 2000-10-03 Vertex Pharmaceuticals Incorporated Molecules comprising an IMPDH-like binding pocket and encoded data storage medium capable of graphically displaying them
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
ATE375363T1 (de) * 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
US6017876A (en) 1997-08-15 2000-01-25 Amgen Inc. Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
CN1061992C (zh) * 1997-11-19 2001-02-14 蒋永平 新的重组人粒细胞集落刺激因子及其药物组合物
CN101070344A (zh) * 1998-04-30 2007-11-14 泰诺士公司 G－csf受体兴奋剂抗体及其筛选方法
TWI242563B (en) * 1998-04-30 2005-11-01 Tanox Inc Monoclonal agonist antibodies which specifically bind to or interact with human G-CSF receptor
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6979442B1 (en) 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US6451346B1 (en) * 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
AU770131B2 (en) * 1999-01-06 2004-02-12 Xencor, Inc. Nucleic acids and proteins corresponding to mutants of G-CSF with granulopoietic activity
US7208473B2 (en) * 1999-01-06 2007-04-24 Xencor, Inc. Nucleic acids and protein variants of hG-CSF with granulopoietic activity
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
JP2002540065A (ja) * 1999-01-29 2002-11-26 アムジェン インコーポレーテッド Ｇｃｓｆコンジュゲート
US6500418B1 (en) * 1999-02-12 2002-12-31 The Washington University Stimulating neutrophil function to treat inflammatory bowel disease
JP2000319298A (ja) * 1999-03-04 2000-11-21 Seibutsu Bunshi Kogaku Kenkyusho:Kk 蛋白質複合体の結晶、構造座標、及び構造座標の使用
US20030022383A1 (en) * 1999-04-06 2003-01-30 Uab Research Foundation Method for screening crystallization conditions in solution crystal growth
US7244396B2 (en) 1999-04-06 2007-07-17 Uab Research Foundation Method for preparation of microarrays for screening of crystal growth conditions
US7214540B2 (en) 1999-04-06 2007-05-08 Uab Research Foundation Method for screening crystallization conditions in solution crystal growth
NZ514732A (en) * 1999-04-06 2004-01-30 Uab Research Foundation Method for screening crystallization conditions in solution crystal growth
US7247490B2 (en) 1999-04-06 2007-07-24 Uab Research Foundation Method for screening crystallization conditions in solution crystal growth
US7250305B2 (en) 2001-07-30 2007-07-31 Uab Research Foundation Use of dye to distinguish salt and protein crystals under microcrystallization conditions
CA2372526A1 (en) * 1999-05-10 2000-11-16 Michael D. Wyrsta Methods and compositions for controlled polypeptide synthesis
US6630006B2 (en) * 1999-06-18 2003-10-07 The Regents Of The University Of California Method for screening microcrystallizations for crystal formation
US6296673B1 (en) * 1999-06-18 2001-10-02 The Regents Of The University Of California Methods and apparatus for performing array microcrystallizations
US7058517B1 (en) 1999-06-25 2006-06-06 Genaissance Pharmaceuticals, Inc. Methods for obtaining and using haplotype data
ATE407697T1 (de) * 1999-07-13 2008-09-15 Bolder Biotechnology Inc Erythropoietin immunglobulin fusionsproteine
US8106098B2 (en) * 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
US6831158B2 (en) * 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
US6646110B2 (en) * 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
SK11672002A3 (sk) * 2000-01-10 2002-12-03 Maxygen Holdings Ltd. Polypeptidový konjugát, spôsob jeho výroby, farmaceutický prostriedok s jeho obsahom a jeho použitie
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
GB0008563D0 (en) * 2000-04-07 2000-05-24 Cambridge Discovery Chemistry Investigating different physical and/or chemical forms of materials
EP1043239B1 (en) * 2000-06-16 2004-02-04 VSI Holding A/S Container with collapsible sides
US6931326B1 (en) 2000-06-26 2005-08-16 Genaissance Pharmaceuticals, Inc. Methods for obtaining and using haplotype data
AU2001286931A1 (en) * 2000-08-30 2002-03-13 The Salk Institute For Biological Studies Methods and compositions for determining isomerase enzymatic activity
EP1354045A2 (en) * 2000-09-07 2003-10-22 Eli Lilly And Company Hyperglycosylated polypeptides
JP4799803B2 (ja) * 2000-09-08 2011-10-26 マサチューセッツ インスティテュート オブ テクノロジー Ｇ−ｃｓｆアナログ組成物および方法
WO2002036626A1 (en) * 2000-11-02 2002-05-10 Maxygen Aps Single-chain multimeric polypeptides
EP1419428A4 (en) * 2001-03-12 2005-03-02 Regents Board Of ENSEMBLE-BASED STRATEGY FOR THE DESIGN OF PROTEIN MEDICINAL PRODUCTS
DE10112825A1 (de) * 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylierung von Wirkstoffen in wässriger Lösung
US7670429B2 (en) 2001-04-05 2010-03-02 The California Institute Of Technology High throughput screening of crystallization of materials
US6998219B2 (en) * 2001-06-27 2006-02-14 University Of South Florida Maskless photolithography for etching and deposition
PL371781A1 (en) * 2001-07-11 2005-06-27 Maxygen Holdings, Ltd. G-csf conjugates
US20030104996A1 (en) * 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
US20040247562A1 (en) * 2001-09-28 2004-12-09 Sang Yup Lee Diagnostic method for cancer characterized in the detection of the deletion of g-csf exon 3
DE10209821A1 (de) * 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
DE10209822A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
JP2006507562A (ja) * 2002-05-23 2006-03-02 ザ ボード オブ レジェンツ−ザ ユニバーシティー オブ テキサス システム アンサンブルベースの構造エネルギーを使用した一塩基多型（ｓｎｐｓ）の意義の予測
WO2004005898A1 (en) * 2002-07-10 2004-01-15 Uab Research Foundation Method for distinguishing between biomolecule and non-biomolecule crystals
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
BR0314106A (pt) * 2002-09-11 2005-07-19 Fresenius Kabi De Gmbh Polipeptìdeos hasilados, especialmente eritropoietina hasilada
DE10242076A1 (de) * 2002-09-11 2004-03-25 Fresenius Kabi Deutschland Gmbh HAS-Allergen-Konjugate
ATE409048T1 (de) * 2002-10-08 2008-10-15 Fresenius Kabi De Gmbh Pharmazeutisch aktive oligosaccharid-conjugate
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
EA008866B1 (ru) * 2002-12-26 2007-08-31 Маунтин Вью Фамэсьютикэлс, Инк. ПОЛИМЕРНЫЙ КОНЪЮГАТ МОДИФИКАЦИЙ ИНТЕРФЕРОНА-β, ФАРМАЦЕВТИЧЕСКИЕ ПРОДУКТЫ НА ЕГО ОСНОВЕ И СПОСОБ ИХ ПОЛУЧЕНИЯ
NZ541122A (en) * 2002-12-26 2008-09-26 Mountain View Pharmaceuticals Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
US7695723B2 (en) 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
DK1648931T3 (da) 2003-07-21 2011-03-07 Transgene Sa Multifunktionelle cytokiner
WO2005014655A2 (en) * 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
EP1653991A2 (en) * 2003-08-08 2006-05-10 Fresenius Kabi Deutschland GmbH Conjugates of a polymer and a protein linked by an oxime linking group
US20090226397A1 (en) 2003-10-24 2009-09-10 Nora Therapeutics, Inc. Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination
EP2441465B1 (en) * 2003-10-24 2014-01-15 Nora Therapeutics, Inc. Compositions and methods for healthy pregnancy
US8338373B2 (en) * 2003-10-24 2012-12-25 Nora Therapeutics, Inc. Method for reducing the risk of spontaneous abortion in a human female subject
US7220407B2 (en) * 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
US20060122784A1 (en) * 2004-12-03 2006-06-08 Ishikawa Muriel Y System and method for augmenting a humoral immune response
JP2007517042A (ja) 2003-12-30 2007-06-28 デュレクト コーポレーション 活性物質、好ましくはｇｎｒｈの制御放出のための、好ましくはｐｅｇおよびｐｌｇの混合物を含有するポリマーインプラント
TWI417303B (zh) 2004-03-11 2013-12-01 Fresenius Kabi De Gmbh 經由還原胺化作用製得之羥烷基澱粉及蛋白質的接合物
WO2005092369A2 (en) * 2004-03-11 2005-10-06 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyethyl starch and erythropoietin
US8603824B2 (en) 2004-07-26 2013-12-10 Pfenex, Inc. Process for improved protein expression by strain engineering
US20060153799A1 (en) * 2004-11-05 2006-07-13 Northwestern University Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders
US7741096B2 (en) * 2004-12-10 2010-06-22 Genentech, Inc. Crystal structure of hepatocyte growth factor activator complexed with Kunitz domain inhibitor
US7790174B2 (en) 2004-12-23 2010-09-07 Merck Serono Sa G-CSF polypeptides and uses thereof
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
KR100657749B1 (ko) * 2005-04-13 2006-12-20 씨제이 주식회사 인간 과립구 콜로니 형성인자 동종체 및 그 조성물
EP1888119B1 (en) * 2005-06-01 2011-03-09 Maxygen, Inc. Pegylated g-csf polypeptides and methods of producing same
KR100694994B1 (ko) * 2005-06-13 2007-03-14 씨제이 주식회사 사람 과립구 콜로니 형성인자 동종체
KR100735784B1 (ko) 2005-07-20 2007-07-06 재단법인 목암생명공학연구소 인간 과립구콜로니자극인자 변이체 및 이의 화학적 접합물
AU2006281638B2 (en) * 2005-08-15 2012-05-03 Phares Pharmaceutical Research N.V. Crystal forms of astaxanthin
WO2007024940A2 (en) * 2005-08-22 2007-03-01 Dana-Farber Cancer Institute, Inc. Mitochondrial localization of muc1
US20070112804A1 (en) * 2005-11-07 2007-05-17 Desimas Bruce E Systems and methods for generating automated software workflows for biological testing
GB0605684D0 (en) * 2006-03-21 2006-05-03 Sicor Biotech Uab Method For Purifying Granulocyte-Colony Stimulating Factor
WO2008111996A2 (en) * 2006-07-20 2008-09-18 Dana-Farber Cancer Institute, Inc. Muc1-ikb kinase complexes and their activities
WO2008097840A2 (en) 2007-02-02 2008-08-14 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of muc1 by hsf1 and stat3
US7871784B2 (en) * 2007-02-02 2011-01-18 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by MUC1 and BH3-containing proapoptotic proteins
JP4375412B2 (ja) * 2007-02-19 2009-12-02 株式会社デンソー 蒸発器ユニット
JP5444553B2 (ja) 2007-04-27 2014-03-19 フェネックス インコーポレイテッド 微生物宿主を迅速にスクリーニングして、異種タンパク質発現の収率および／または質が改善されている特定の株を同定する方法
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
JP5244175B2 (ja) 2007-07-03 2013-07-24 アムジエン・インコーポレーテツド 封入体乾燥重量を用いたタンパク質の測定
KR20190140090A (ko) 2007-07-09 2019-12-18 제넨테크, 인크. 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
EP2578677A1 (en) 2007-08-09 2013-04-10 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
US8758761B2 (en) * 2007-09-30 2014-06-24 University Of Florida Research Foundation, Inc. Combination therapies for treating type 1 diabetes
US8570393B2 (en) * 2007-11-30 2013-10-29 Cognex Corporation System and method for processing image data relative to a focus of attention within the overall image
EP2070950A1 (en) * 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkyl starch derivatives and process for their preparation
EP2070951A1 (en) * 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Method for producing a hydroxyalkyl starch derivatives with two linkers
NZ586947A (en) 2008-02-08 2012-11-30 Ambrx Inc Modified leptin polypeptides and their uses
WO2009103199A1 (zh) 2008-02-18 2009-08-27 江苏恒瑞医药股份有限公司 水溶性聚合物修饰的g-csf偶联物
EP2296690B1 (en) 2008-06-04 2016-11-30 Amgen, Inc Fgf21 mutants and uses thereof
EP2323688B1 (en) 2008-07-22 2018-10-17 MenoGeniX, Inc. Compositions and methods for treating symptoms associated with menopause, hormonal variations and arthritis
PT2318029T (pt) 2008-07-23 2018-01-10 Ambrx Inc Polipéptidos de g-csf bovino modificados e suas utilizações
US9151289B2 (en) 2008-08-21 2015-10-06 Cummins Inc. Fuel pump
JP5878757B2 (ja) 2008-10-10 2016-03-08 アムジエン・インコーポレーテツド Ｆｇｆ２１変異体およびその使用
KR101689408B1 (ko) 2008-10-17 2016-12-23 다나-파버 캔서 인스티튜트 인크. 암의 저해제로서 ｍｕｃ-1 세포질 도메인 펩티드
US9189670B2 (en) * 2009-02-11 2015-11-17 Cognex Corporation System and method for capturing and detecting symbology features and parameters
EP2427207B1 (en) 2009-05-05 2017-08-16 Amgen, Inc Fgf21 mutants and uses thereof
HRP20240135T1 (hr) * 2009-05-05 2024-04-12 Amgen Inc. Fgf21 mutanti i njihove upotrebe
US8324160B2 (en) * 2009-06-17 2012-12-04 Amgen Inc. Chimeric polypeptides and uses thereof
EP2679234A3 (en) 2009-12-02 2014-04-23 Amgen Inc. Binding proteins that bind to human FGFR1C, human beta-klotho and both human FGFR1C and human beta-klotho
UA109888C2 (uk) * 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
JP2013515081A (ja) 2009-12-21 2013-05-02 アンブルックス，インコーポレイテッド 修飾されているブタのソマトトロピンポリペプチドおよびそれらの使用
NZ600361A (en) 2009-12-21 2014-06-27 Ambrx Inc Modified bovine somatotropin polypeptides and their uses
US8952054B2 (en) 2010-03-15 2015-02-10 Dana-Farber Cancer Institute, Inc. Small molecule inhibitors of MUC1 and methods of identifying the same
JP5714692B2 (ja) 2010-03-23 2015-05-07 イーエムベーアー−インスティトゥート・フューア・モレクラレ・ビオテヒノロギー・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＩｍｂａ−Ｉｎｓｔｉｔｕｔ Ｆｕｅｒｍｏｌｅｋｕｌａｒｅ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅ Ｇｍｂｈ Ｉｉｉ型分泌機構の阻害剤の同定方法
CA2796055A1 (en) 2010-04-15 2011-10-20 Amgen Inc. Human fgf receptor and .beta.-klotho binding proteins
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
ES2630031T3 (es) 2010-09-28 2017-08-17 Aegerion Pharmaceuticals, Inc. Un polipéptido de leptina pinnípedo-humano quimérico con solubilidad aumentada
US8889630B2 (en) 2011-12-23 2014-11-18 Carlos Lopez Method for hair regrowth using Granulocyte-Colony Stimulating Factor
WO2014045126A2 (en) 2012-09-18 2014-03-27 Uti Limited Partnership Treatment of pain by inhibition of usp5 de-ubiquitinase
PT3524617T (pt) 2013-03-15 2023-07-12 Gladiator Biosciences Inc Domínios gla como agentes terapêuticos
LT6161B (lt) 2013-09-27 2015-06-25 Uab Profarma Granuliocitų kolonijas stimuliuojančio faktoriaus sulieti baltymai su kitais augimo faktoriais, optimaliai su kamieninių ląstelių faktoriumi, ir jų gavimo būdas
WO2015057724A1 (en) 2013-10-14 2015-04-23 Nora Therapeutics, Inc. Use of g-csf for treating or preventing villitis of unknown etiology in a human female
JP2018519359A (ja) * 2015-06-11 2018-07-19 アンビオ ファーマシューティカルズ，エルエルシー Ｐｅｇ化顆粒球コロニー刺激因子（ｇｃｓｆ）
AU2016342209B2 (en) * 2015-10-19 2020-12-17 Sandoz Ag Improved coding sequence for human G-CSF
SG11202001535RA (en) 2017-09-05 2020-03-30 Gladiator Biosciences Inc Method of targeting exosomes
CN108384747A (zh) * 2018-03-05 2018-08-10 安徽省农业科学院园艺研究所 表达狂犬抗体的cho细胞无血清悬浮培养方法
EP4041760A4 (en) * 2019-10-08 2023-10-11 Zymeworks BC Inc. Modified extracellular domain of granulocyte colony-stimulating factor receptor (g-csfr) and cytokines binding same
WO2021123033A1 (en) 2019-12-17 2021-06-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Novel g-csf mimics and their applications

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
WO1985000817A1 (en) * 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS6263335A (ja) * 1985-09-13 1987-03-20 Fuji Photo Film Co Ltd 化学反応情報の処理方法
US4908773A (en) * 1987-04-06 1990-03-13 Genex Corporation Computer designed stabilized proteins and method for producing same
DK203187A (da) * 1986-04-22 1987-10-23 Immunex Corp Human g-csf proteinekspression
AU7675487A (en) * 1986-08-11 1988-05-19 Cetus Corporation Expression of granulocyte colony-stimulating factor
US4704692A (en) * 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
DK174044B1 (da) * 1986-12-23 2002-05-06 Kyowa Hakko Kogyo Kk Polypeptid afledt fra human granulocytkolonistimulerende faktor, og fremgangsmåde til fremstilling deraf, DNA kodende for nævnte polypeptid, rekombinant plasmid indeholdende nævnte DNA, og mikroorganismer indeholdende nævnte rekombinante plasmid.......
US4853871A (en) * 1987-04-06 1989-08-01 Genex Corporation Computer-based method for designing stablized proteins
GB2213821B (en) * 1987-12-23 1992-01-02 British Bio Technology Synthetic human granulocyte colony stimulating factor gene
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5153265A (en) * 1988-01-20 1992-10-06 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
CA1340810C (en) * 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
EP0344796B1 (en) * 1988-06-03 1994-09-21 Chugai Seiyaku Kabushiki Kaisha Crystalline human granulocyte colony stimulating factor and process for preparing the same
US5025388A (en) * 1988-08-26 1991-06-18 Cramer Richard D Iii Comparative molecular field analysis (CoMFA)
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5109119A (en) * 1989-06-06 1992-04-28 Schering Corporation Crystalline r-h-gm-csf and method
US5265030A (en) * 1990-04-24 1993-11-23 Scripps Clinic And Research Foundation System and method for determining three-dimensional structures of proteins
GB9107846D0 (en) 1990-04-30 1991-05-29 Ici Plc Polypeptides
DE4014750A1 (de) * 1990-05-08 1991-11-14 Boehringer Mannheim Gmbh Muteine des granulozyten-stimulierenden faktors (g-csf)
JP3249147B2 (ja) 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
IE912365A1 (en) 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
DK0546124T4 (da) * 1990-08-29 2003-05-19 Inst Genetics Llc Hæmatopoiese-stimulatorer med flere domæner
US5124297A (en) 1990-12-07 1992-06-23 Amoco Corporation Olefin polymerization and copolymerization catalyst
DE4105480A1 (de) 1991-02-21 1992-08-27 Boehringer Mannheim Gmbh Verbesserte aktivierung von rekombinanten proteinen
WO1992016555A1 (en) * 1991-03-18 1992-10-01 Enzon, Inc. Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
US5157736A (en) * 1991-04-19 1992-10-20 International Business Machines Corporation Apparatus and method for optical recognition of chemical graphics
US5386507A (en) * 1991-07-18 1995-01-31 Teig; Steven L. Computer graphics system for selectively modelling molecules and investigating the chemical and physical properties thereof
AU666866B2 (en) * 1991-08-30 1996-02-29 Fred Hutchinson Cancer Research Center Hybrid cytokines
JP2638359B2 (ja) * 1991-11-26 1997-08-06 富士通株式会社 分子動力学法の拘束条件作成装置
EP0955365A3 (en) * 1992-06-09 2000-12-20 Chiron Corporation Crystallization of M-CSF
US5772992A (en) 1992-11-24 1998-06-30 G.D. Searle & Co. Compositions for co-administration of interleukin-3 mutants and other cytokines and hematopoietic factors
US6057133A (en) 1992-11-24 2000-05-02 G. D. Searle Multivariant human IL-3 fusion proteins and their recombinant production
US6153183A (en) 1992-11-24 2000-11-28 G. D. Searle & Company Co-administration of interleukin-3 mutant polypeptides with CSF's or cytokines for multi-lineage hematopoietic cell production
EP0672145B1 (en) 1992-11-24 2003-04-23 G.D. Searle & Co. Interleukin-3 (il-3) multiple mutation polypeptides
US5738849A (en) 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
US5424963A (en) * 1992-11-25 1995-06-13 Photon Research Associates, Inc. Molecular dynamics simulation method and apparatus
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US5635599A (en) 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JPH11500308A (ja) 1995-02-03 1999-01-12 ジー．ディー．サール アンド カンパニー 新規ｃ−ＭＰＬリガンド
US6017523A (en) 1995-06-06 2000-01-25 G.D. Searle & Co. Therapeutic methods employing mutant human interleukin-3 (IL-3) polypeptides
CN1590407A (zh) 1995-10-05 2005-03-09 G.D.瑟尔公司 多功能性造血受体激动剂
US6066318A (en) 1995-10-05 2000-05-23 G.D. Searle & Co. Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors
EP0870027A1 (en) 1995-10-05 1998-10-14 G.D. Searle & Co. Novel c-mpl receptor agonists
US6100070A (en) 1995-10-05 2000-08-08 G. D. Searle & Co. G-CSF receptor agonists
AU717733B2 (en) 1995-10-05 2000-03-30 G.D. Searle & Co. Novel G-CSF receptor agonists
US5969105A (en) 1996-10-25 1999-10-19 Feng; Yiqing Stem cell factor receptor agonists
NZ335382A (en) 1996-10-25 2001-03-30 Searle & Co Multi-functional chimeric hematopoietic polypeptides of IL-3, GCSF, Flt3L, EPO, stem cell factor, cmpl link with or without linker group consisting of Alanine, Glycine and/or Serine for treating autoimmune and tumour related diseases
US6660257B1 (en) 1996-10-25 2003-12-09 Pharmacia Corporation Circular permuteins of flt3 ligand
CA2284127A1 (en) 1997-04-11 1998-10-22 G.D. Searle & Co. Flt3 ligand chimeric proteins
EP1115854A1 (en) 1998-09-25 2001-07-18 G.D. Searle & Co. Method of producing permuteins by scanning permutagenesis
US6555660B2 (en) 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
EP2042196B1 (en) * 2001-10-10 2016-07-13 ratiopharm GmbH Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF)

Also Published As

Publication number Publication date
EP0974655A3 (en) 2001-10-24
ATE553199T1 (de) 2012-04-15
DE69425516T2 (de) 2001-06-13
WO1994017185A1 (en) 1994-08-04
CA2153896C (en) 1999-01-12
IL145994A0 (en) 2002-07-25
EP1482046A2 (en) 2004-12-01
US20010016191A1 (en) 2001-08-23
JP2010059170A (ja) 2010-03-18
US20050260154A1 (en) 2005-11-24
GR3034745T3 (en) 2001-02-28
US7381804B2 (en) 2008-06-03
CA2239360A1 (en) 1994-08-04
JP2009057368A (ja) 2009-03-19
FI20090384L (fi) 2009-10-21
LV12642A (lv) 2001-04-20
JPH08506018A (ja) 1996-07-02
NZ332188A (en) 2000-07-28
US20030171559A1 (en) 2003-09-11
CA2239360C (en) 2002-07-16
EP2345724A1 (en) 2011-07-20
LU92265I2 (fr) 2013-10-14
DK1482046T3 (da) 2012-06-25
CN1118572C (zh) 2003-08-20
IL108446A0 (en) 1994-04-12
DE69425516D1 (de) 2000-09-21
EP0965638A3 (en) 2000-02-23
LV12642B (en) 2001-09-20
NZ513422A (en) 2002-09-27
NO952974D0 (no) 1995-07-27
CN1970571B (zh) 2013-07-10
KR100390338B1 (ko) 2003-07-07
AU6095794A (en) 1994-08-15
AU8197098A (en) 1998-10-15
FI953593A0 (fi) 1995-07-27
JP2011207885A (ja) 2011-10-20
US8058398B2 (en) 2011-11-15
JP2006096762A (ja) 2006-04-13
JP2004113243A (ja) 2004-04-15
EP0612846B1 (en) 2000-08-16
US6261550B1 (en) 2001-07-17
IL124112A (en) 2006-12-10
CN1132527A (zh) 1996-10-02
US5581476A (en) 1996-12-03
NO20031497L (no) 2003-04-02
KR100375274B1 (ko) 2003-06-11
PT612846E (pt) 2001-01-31
NZ314960A (en) 1999-01-28
NO20031497D0 (no) 2003-04-02
ATE195552T1 (de) 2000-09-15
ES2150951T3 (es) 2000-12-16
US6632426B2 (en) 2003-10-14
JP2006137762A (ja) 2006-06-01
ES2422269T3 (es) 2013-09-10
PT1482046E (pt) 2012-06-06
CA2711007C (en) 2012-10-02
CN1495197A (zh) 2004-05-12
EP1233065A1 (en) 2002-08-21
EP2345724B1 (en) 2013-07-03
FI123078B (fi) 2012-10-31
HK1107356A1 (en) 2008-04-03
EP0612846A1 (en) 1994-08-31
EP0965638A2 (en) 1999-12-22
FI953593L (fi) 1995-07-27
HK1009288A1 (en) 1999-05-28
EP1482046B1 (en) 2012-04-11
FI120769B (fi) 2010-02-26
EP0890640A3 (en) 1999-03-24
ES2382927T3 (es) 2012-06-14
KR960700341A (ko) 1996-01-19
CN1495197B (zh) 2013-01-16
CA2711007A1 (en) 1994-08-04
NO20093489L (no) 1995-09-28
IL108446A (en) 2003-01-12
EP1482045A2 (en) 2004-12-01
EP0890640A2 (en) 1999-01-13
CA2381489A1 (en) 1994-08-04
IL145994A (en) 2010-12-30
EP0974655A2 (en) 2000-01-26
CN1970571A (zh) 2007-05-30
CA2381489C (en) 2010-10-19
DK2345724T3 (da) 2013-09-30
PT2345724E (pt) 2013-08-22
EP1482046A3 (en) 2005-01-05
NZ261765A (en) 1997-10-24
CA2153896A1 (en) 1994-08-04
EP1482045A3 (en) 2004-12-29
ZA94568B (en) 1994-09-12
NZ504840A (en) 2001-11-30
DK0612846T3 (da) 2000-10-09
IL124111A (en) 2002-09-12
AU697451B2 (en) 1998-10-08
IL125398A0 (en) 1999-03-12
US5790421A (en) 1998-08-04

Similar Documents

Publication Publication Date Title
NO952974D0 (no) G-CSF-analogpreparater og fremgangsmåter
NO960309L (no) Agonister og antagonister for humaninterleukin-10
HUP0104717A2 (hu) Készítmények és eljárások petefészekrák terápiájára és diagnózisára
AU2790292A (en) Viral recombinant vectors for expression in muscle cells
GR80840B (en) Novel polypeptide with a - amylase inhibiting effect, method for the preparation thereof, use and pharmaceutical preparations thereof
FI863971A0 (fi) Farmaceutisk komposition anvaendbar vid behandling av leukopenia.
LTIP1753A (en) Dna sequences coding for proteins, biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
IT9020072A0 (it) Cellule umane per l'elevata espressione di geni inseriti in dna ricombinanti episomiali,loro preparazione e loro impiego
NO890174L (no) Rekombinante interleukin-1alfa-polypeptider.
EP0676413A3 (en) Interferon alpha / beta binding protein, its production and application.
ATE87314T1 (de) Platin-arzneimittel.
ATE55411T1 (de) Menschliches antithrombin iii, dns sequenzen dafuer, expressions- und klonierungsvektoren die solche sequenzen enthalten und damit transformierte zellkulturen, verfahren zur expression von menschlichem antithrombin iii und diese enthaltende pharmazeutische zusammensetzungen.
JPS6458056A (en) Editing device

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application
FC2A Withdrawal, rejection or dismissal of laid open patent application